Zoltan Matrai

Pest, BU, Hungary

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Editor's Note: B-Cell Receptor Translocation to Lipid Rafts and Associated Signaling Differ Between Prognostically Important Subgroups of Chronic Lymphocytic Leukemia.

Editor's Note: B-Cell Receptor Translocation to Lipid Rafts and Associated Signaling Differ Between Prognostically Important Subgroups of Chronic Lymphocytic Leukemia.

Journal: Cancer research
Published: March 23, 2026

Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 29, 2025

Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 27, 2025

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 06, 2025

Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.

Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.

Journal: Leukemia
Published: January 12, 2023

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.

Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.

Journal: Leukemia
Published: October 11, 2022

Secondary malignancies and survival of FCR-treated patients with chronic lymphocytic leukemia in Central Europe.

Secondary malignancies and survival of FCR-treated patients with chronic lymphocytic leukemia in Central Europe.

Journal: Cancer medicine
Published: January 25, 2022

Screening and monitoring of the BTKC481S mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.

Screening and monitoring of the BTKC481S mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.

Journal: British journal of haematology
Published: January 25, 2021

Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.

Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.

Journal: Pathology
Published: December 04, 2020

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL.

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL.

Journal: Nature communications
Published: April 01, 2019

Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.

Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.

Journal: International journal of cancer
Published: January 04, 2019

Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia.

Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia.

Journal: Haematologica
Published: September 29, 2018
Showing 1-12 of 16

Last Updated: 09/26/2026